|
|
|
|
|
|
|
|
Conclusion: PARP inhibitors show promise as a powerful therapeutic tool, especially in the management of BRCA-associated breast and ovarian cancers but also in tumours where BRCA genes may be dysfunctional. Clinical studies are ongoing and many translational questions remain unanswered that will help clarify how to determine the best way to use PARP inhibitors.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.